Abstract Contralateral prophylactic mastectomy (CPM) refers to removal of the opposite uninvolved breast in women with unilateral breast cancer, and rates are increasing worldwide. In observational studies, CPM is often associated with reductions in breast cancer-specific and all-cause mortality when compared to unilateral surgical treatment alone, but this may reflect selection of a healthier cohort for CPM (selection bias). To further explore this possibility, we examined the association between CPM and non-cancer mortality, an indicator of selection bias. We identified 449,178 adult women diagnosed with unilateral, primary American Joint Committee on Cancer (AJCC) stage I-III ductal or lobular breast cancer, utilizing the 1998-2010 Surveillance, Epidemiology, and End Results dataset. Of these, 5.8 % (n = 25,961) underwent CPM as their first course of treatment. We examined associations between CPM and breast cancerspecific, all-cause, and non-cancer mortality utilizing multivariate logistic regression, adjusting for age, race, AJCC stage, estrogen receptor status, progesterone receptor status, and histologic grade of the tumor. Among all patients receiving CPM as first course of treatment, CPM was associated with lower breast cancer-specific [HR 0. are consistent with other observational studies showing associations between CPM and reductions in breast cancerspecific and all-cause mortality, we demonstrate an even stronger association between CPM and reduced non-cancer mortality. Thus, the reported associations between CPM and reductions in mortality might at least partly be attributable to selection bias.
Background
Contralateral prophylactic mastectomy (CPM) refers to the removal of the opposite uninvolved breast in women with unilateral breast cancer, and rates are dramatically increasing worldwide [1] [2] [3] [4] [5] [6] . Moreover, there is now a large body of evidence, derived entirely from observational studies, suggesting that CPM is associated with reductions in breast cancer-specific and all-cause mortality when compared to unilateral surgical treatment alone, even after adjusting for measured confounding variables [7] [8] [9] [10] [11] [12] [13] . This association has been demonstrated not only in women with early stage unilateral breast cancer with an increased risk of developing contralateral breast cancer (such as BRCA1/ BRCA2 mutation carriers and those with estrogen receptor negative tumors), but also in patients at average risk for developing contralateral breast cancer.
Yet, observational studies rely on datasets that often omit important covariates linked to outcomes, thereby producing biased estimates of treatment effects [14] . For instance, healthier women (who are better able to withstand a longer surgical procedure) and those from higher socioeconomic backgrounds (with better healthcare access) might be preferentially selected for CPM, but such confounders are generally not measured and recorded in datasets. Thus, the results of observational studies demonstrating an association between CPM and lower breast cancer-specific and all-cause mortality might, at least in part, be attributable to unmeasured confounders (selection bias).
To further explore this possibility, we examined associations between CPM and breast cancer-specific, all-cause, and non-cancer mortality, utilizing Surveillance, Epidemiology, and End Results (SEER), a large population-based dataset. If CPM was having the intended treatment effect, it should lower breast cancer-specific and all-cause mortality, but not lower non-cancer mortality as it is not expected to reduce non-cancer risk factors for death (e.g., heart disease, stroke). Therefore, an association between CPM and reduced non-cancer mortality would suggest a selection bias favoring women who undergo CPM and indicate that there may be unmeasured factors contributing to the previously identified associations between CPM and lower breast cancer-specific and all-cause mortality.
A previous study utilized an earlier version of the SEER dataset and evaluated associations between CPM and breast cancer-specific and non-cancer mortality in agestratified cohorts, but not across all age groups [9] . CPM was associated with significant reductions in non-cancer deaths in older but not younger women. The authors concluded that a bias exists for selecting healthier older women for CPM, but that such a bias could not account for the association between CPM and lower breast cancerspecific mortality in younger women. Yet, the results of this study might be event-driven. As older women are more likely to experience non-cancer deaths than younger women, a significant association between CPM and noncancer mortality is more likely to be detected in older women. We have therefore utilized a more recent and expanded version of the SEER dataset to examine associations between CPM and breast cancer-specific, overall, and non-cancer mortality across all age groups. In our opinion, the overall association between CPM and noncancer mortality should be a more reliable indicator of selection bias, irrespective of age.
As it is highly unlikely that there will ever be a randomized trial addressing the effect of CPM on breast cancer mortality, the validity of observational studies addressing this issue remains an important consideration.
Methods

Data source
We used the 1998-2010 SEER data for our study [15] . SEER collects cancer incidence and survival data from population-based cancer registries representing approximately 26 % of the US population including patient characteristics, primary tumor site, tumor stage and grade, first course of treatment (including surgery and irradiation, with information on contralateral prophylactic mastectomy beginning in 1998), lymph node status, and survival. First course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.
Patients
We included women diagnosed between 18 and 90 years of age with their first invasive, non-metastatic, ductal or lobular carcinoma of the breast from January 1, 1998 through December 31, 2010. Patients were excluded if they had unknown microscopic confirmation of the tumor (n = 52); were diagnosed with bilateral breast cancer (n = 49); had an unknown length of survival (n = 0); or had their cancer first diagnosed in a nursing home, on autopsy or first cited on the death certificate (as these patients would unlikely undergo treatment for their cancer) (n = 16). Our final study sample included 449,178 adult women diagnosed with unilateral, primary American Joint Committee on Cancer (AJCC) stage I-III ductal or lobular breast cancer.
Variable definitions
CPM
CPM was defined in SEER as the removal of an uninvolved contralateral breast in women with unilateral breast cancer using total (simple), radical or modified radical mastectomy, as part of the first course of treatment.
Mortality
Five-year, cause-specific mortality was defined using a combination of the SEER-reported survival time, in months, combined with the cause of death cited on the death certificate. Mortality was further classified as allcause mortality (i.e., death from any cause), breast cancerspecific mortality (i.e. death from breast cancer), and noncancer mortality (i.e., death from a cause other than cancer).
Patient demographics
Each patient was classified according to reported demographics available in SEER, which included age and race. Age was evaluated as a continuous variable, while race was categorized as: White, Black, or Other. 
Statistical analysis
We first examined the unadjusted association between patient and tumor characteristics and receipt of CPM using Chi-square tests for categorical variables and t tests for continuous variables. Next, we used multivariate logistic regression to examine the adjusted association between patient and tumor characteristics and receipt of CPM, after adjusting for age, race, AJCC stage, estrogen receptor status, progesterone receptor status, and histologic grade. Finally, multivariate Cox proportional hazards modeling was used to assess the association between the use of CPM and the 5-year relative hazard of (1) all-cause, (2) breast cancer-specific, and (3) non-cancer hazard of death, after adjusting for age, race, AJCC stage, estrogen receptor status, progesterone receptor status, and histologic grade. Data retrieval, cleaning, and statistical analysis were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). P values B 0.05 were considered statistically significant. This study was approved by the University of Texas Health Science Center at San Antonio Institutional Review Board.
Results
In our study of 449,178 adult women diagnosed with unilateral, primary AJCC stage I-III ductal or lobular breast cancer in the SEER cancer registries, we found that 5.8 % (n = 25,961) of patients received CPM as part of their first course of treatment (Table 1) . Overall, the mean age at diagnosis in our cohort was 59.5. The majority of the study population was White (82.2 %), AJCC stage I (48.8 %), estrogen receptor positive (72.2 %), progesterone receptor positive (60.8 %), and had low-grade disease (59.2 % with histologic grades I-II) ( Table 1) .
Patient demographic and cancer characteristics associated with receiving CPM
In univariate analysis, CPM was more common in women who were younger at diagnosis (mean age: CPM, 51.1 years Association between receiving CPM and mortality Among all patients, the all-cause 5-year mortality rate was 14.3 %, while the 5-year breast cancer mortality rate and non-cancer mortality rates were 7.9 and 5.7 %, respectively ( however, the relationship between CPM and non-cancer mortality was stronger than either all-cause or breast cancer-specific mortality (Table 3) . This relationship was consistent when stratified by AJCC stage.
Discussion
In our multivariate analysis of non-metastatic breast cancer patients diagnosed in the SEER cancer registries between 1998 and 2010, we found that first course of treatment with CPM was associated with significant reductions in breast cancer-specific, all-cause, and non-cancer mortality when compared to unilateral surgical treatment alone. However, the significant association between CPM and reduced noncancer mortality, coupled with the stronger association between CPM and reduced non-cancer mortality relative to both breast cancer-specific and all-cause mortality, suggests an underlying selection bias for treating potentially healthier women with CPM. As a result, the previously reported associations between CPM and reductions in breast cancer-specific and all-cause mortality may partly be attributed to unmeasured factors (i.e., confounders). Contralateral breast cancers are generally regarded as new primary cancers, and not metastases from the opposite breast [16] . If contralateral breast cancers were simply a manifestation of distant metastases, then CPM should not have an effect in reducing mortality. Among women with unilateral early stage breast cancer, the risk of developing a contralateral cancer varies according to patient and tumor characteristics. Thus, for BRCA1/BRCA2 mutation carriers with early stage breast cancer that risk is about 2 % per year or approximately 20 % over a 10-year period, while for non-mutation carriers that risk is less than 5 % over the same period [17, 18] . As the majority of women can be effectively treated following diagnosis of a contralateral breast cancer then, at least in theory, the absolute benefit of CPM on breast cancer mortality should not exceed 4 % for the BRCA mutation carrier or 1 % for the average risk patient over a 10-year period [17] . Yet, observational studies generally show much larger benefits, which call into question the validity of such studies.
Worldwide, CPM rates are increasing, and several factors may account for this trend [19] . Firstly, there has been greater use of genetic testing, and CPM is often recommended for women who harbor mutations (such as BRCA 1 and BRCA 2) that increase risk for contralateral breast cancer [20] . Yet, many women who undergo CPM appear to be at low-to-moderate risk for developing contralateral breast cancer, so the wider use of genetic testing can only partly account for the trend toward greater utilization of CPM [21] . Secondly, some patients may overestimate their risk of developing contralateral breast cancer, and experience considerable anxiety over this issue [21, 22] . In this regard, it is somewhat ironic that CPM rates are increasing during a period, when contralateral breast cancer rates are decreasing due to better adjuvant systemic therapies [19] . Thirdly, wider use of pre-operative breast MRI has increased the likelihood of detecting potentially suspicious lesions in the opposite breast, and this may prompt CPM [23] . Indeed, there is evidence that women who have a preoperative breast MRI are twice as likely to choose CPM [24] . Fourthly, due to improvements in breast reconstruction techniques, we may see increases in rates of CPM as women may prefer the better symmetry associated with bilateral mastectomy and reconstruction versus unilateral mastectomy and reconstruction [19] . Finally, several observational studies have demonstrated associations between CPM and reductions in breast cancerspecific and all-cause mortality, and these reports may influence treatment decisions [7] [8] [9] [10] [11] [12] [13] . These associations are evident not only in women with early stage breast cancer who harbor the BRCA1/BRCA2 mutations and those with ER-negative tumors, but also breast cancer patients in the general population. Our study is consistent with such previous reports, but we also demonstrate an even stronger association between CPM and reduced noncancer deaths, which cannot be attributed to CPM. The strong and consistent association with lower non-cancer mortality, even after adjusting for potential confounders, suggests that unmeasured confounders (rather than CPM itself) are at least partly responsible for the associations between CPM and reduced breast cancer-specific and overall mortality.
In our multivariate regression model, we have adjusted for covariates included in the dataset, specifically age, race, and tumor characteristics (AJCC stage, ER/PR status, and histologic grade). Some reports suggest that women with advanced stage disease (stage III, with shorter lifespan) are less likely to undergo CPM than those with earlier stage disease (stage I or II, with longer lifespan), and that the associations between CPM and reductions in breast cancerspecific and all-cause mortality might be attributable to the confounding effect of stage at diagnosis [21, 25] . Yet, in our study, women with higher AJCC stage disease were more likely to undergo CPM, and the association between CPM and lower breast cancer-specific, overall, and noncancer mortality persists even after adjusting for stage. We have not included patients who initially present with metastatic disease (stage IV) in our analyses, as these patients are generally treated with systemic therapy alone, and recent trials indicate that local therapy does not reduce mortality in these patients [26] .
Other potential confounders, not included in our multivariate model, should also be considered. Specifically, one might wonder whether the type of surgery performed on the ipsilateral breast (for the primary cancer) influences the decision to undergo CPM and mortality. However, women who choose CPM will almost invariably undergo an ipsilateral mastectomy (and not lumpectomy), and the extent of axillary surgery is unlikely to have an effect on the decision to undergo CPM or on mortality. Also, it has been pointed out that women may undergo CPM any time after a diagnosis of unilateral breast cancer, and therefore, longterm survivors of unilateral breast cancer are more likely to undergo CPM than short-term survivors (survivor bias) [17] . Yet, survivor bias is unlikely to have confounded the results of our study because the SEER dataset generally only includes treatments during the first year following diagnosis. Finally, other covariates not measured in our dataset, such as socioeconomic status, general health, and access to health care, are potential confounders that may partly account for the association between CPM and lower mortality.
Systematic biases are common in all observational studies, but often difficult to discern [27] . Selection bias implies a lack of comparability between study groups, and is attributable to a wide range of measured as well as AHR adjusted hazard ratio, CI confidence interval unmeasured variables [28] . Such confounders create imbalances between two groups in a study, and produce biased estimates of treatment effects. In this observational study, we provide evidence for a selection bias favoring women who undergo CPM. The persistence of an association between CPM and non-cancer mortality, even in our multivariate regression model (where we account for potential measured confounders in our dataset), suggests that unmeasured confounders are at least partly responsible for associations between CPM and reduced breast cancerspecific and all-cause mortality [29] .
There are limitations to our study, and our results should be interpreted with some caution. Evidence of selection bias does not exclude the possibility of CPM having a real benefit in lowering breast cancer-specific and all-cause mortality. Moreover, we have examined the effect of CPM in a single large population-based dataset, and there might be other datasets where the association between CPM and non-cancer mortality is lacking (and therefore, evidence of the beneficial effect of CPM is more compelling). For instance, the incidence of contralateral breast cancer is much higher in women who harbor the BRCA1/BRCA2 mutations, and CPM may have a real benefit in reducing mortality in these patients.
A randomized prospective trial would be required to minimize the effect of selection bias and determine whether CPM has a real benefit on cause-specific and all-cause mortality. Such a trial is unlikely, as women would probably not agree to randomization, so the true effect of CPM on breast cancer-specific and all-cause mortality will likely never be completely understood. Yet, our study suggests that observational studies produce biased estimates of the effect of CPM. Faced with the diagnosis of unilateral breast cancer, a woman may choose CPM for a variety of reasons, but she should not do so simply on the basis of observational studies demonstrating associations with reduced breast cancer-specific and all-cause mortality.
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